PLA2R IgG test results provide physicians the information needed to help differentiate a diagnosis of primary membranous nephropathy (MN) from secondary MN. ARUP’s cell-based immunofluorescence antibody methodology provides a reliable, robust, semi-quantitative test result that helps physicians evaluate disease activity and clinical course, monitor therapeutic response, and provide risk assessment before and after kidney transplantation.
Membranous nephropathy is one of the most common causes of nephrotic syndrome. Circulating autoantibodies against PLA2R were found in 70–80% of patients with primary MN, but not in those with secondary MN or other renal diseases, making the PLA2R assay integral for managing care of MN patients.
- Occurs in 1 out of 100,000 individuals.
- Seen in all ethnic/racial groups, in both sexes, and at any age.
- More common after age 40, with a higher prevalence seen in white males.